Matt Holt New Mountain Capital Announces Strategic Shifts

New Mountain Capital, a leading investment firm, has made some significant changes under the leadership of Matt Holt.

The firm has announced strategic shifts in its investment approach.

These shifts are aimed at enhancing the firm's ability to deliver long-term returns to its investors.

Matt Holt has been instrumental in driving these changes, leveraging his expertise to position the firm for future success.

The changes are centered around a more focused investment strategy, allowing the firm to be more selective in its investments.

New Mountain Capital is well-positioned to capitalize on these shifts, thanks to its experienced team and robust investment platform.

Matt Holt, Managing Director and President of Private Equity at New Mountain Capital, is excited to build Apixio into a 'connected care' platform.

Apixio is a leading healthcare technology company that offers a differentiated value proposition using machine learning and analytics.

New Mountain Capital is well positioned to ensure Apixio continues to support the success of its clients given their sector expertise and long-term focus.

New Mountain Capital has established Swoop as an independent company, a move that's been four years in the making. Swoop was previously a unit of Real Chemistry, another New Mountain portfolio company.

This change will allow Swoop to focus on its own growth and development, leveraging its proprietary audience targeting, conversational AI systems, and omnichannel engagement solutions. Swoop's first-of-its-kind tools enable pharmaceutical and life sciences brands to find, target, and engage with their ideal patient and provider audiences.

New Mountain Capital will continue to support Swoop as a standalone business, providing additional investment flexibility to pursue exciting roadmaps for expansion. This partnership will allow Swoop to hyper-focus on driving privacy-safe innovation and expanding its best-in-class capability set.

The establishment of Swoop as an independent company represents an exciting next step in the evolution of the healthcare industry. New Mountain Capital is thrilled with the progress to date and looks forward to continuing to support the growth of both Swoop and Real Chemistry as industry-leading platforms.

Centene Corporation has signed a definitive agreement to divest Apixio to New Mountain Capital. This marks a significant step in the company's ongoing portfolio review.

Apixio is a leading healthcare technology company that uses machine learning and analytics to improve administrative, clinical, and financial outcomes for health plans and provider groups. With its patented data science infrastructure, Apixio analyzes structured and unstructured data to develop high-fidelity patient health profiles.

The sale is subject to customary closing conditions, including regulatory approvals. This will likely involve a thorough review of the transaction by relevant authorities to ensure it meets all necessary requirements.

Centene has been a trusted business partner with Apixio since 2015, and the company is confident that New Mountain Capital is well-positioned to ensure Apixio continues to support its clients' success. New Mountain Capital plans to build Apixio into a "connected care" platform that brings together critical infrastructure to enable the shift to outcomes-based reimbursement models.